About Signal Genetics (NASDAQ:MGEN)
Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company's diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual's long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company's MyPRS test provides a whole-genomic expression profile of a patient's multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.
Industry, Sector and Symbol
Industry Medical Laboratories & Research
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$3.34 million
Price / Sales53.70
Price / CashN/A
Book Value$1.75 per share
Price / Book4.59
Return on Equity-80.31%
Return on Assets-64.59%
Frequently Asked Questions for Signal Genetics (NASDAQ:MGEN)
What is Signal Genetics' stock symbol?
Signal Genetics trades on the NASDAQ under the ticker symbol "MGEN."
How were Signal Genetics' earnings last quarter?
Signal Genetics, Inc. (NASDAQ:MGEN) issued its quarterly earnings data on Wednesday, November, 8th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.39) by $0.12. The medical research company earned $1.63 million during the quarter, compared to the consensus estimate of $0.72 million. Signal Genetics had a negative return on equity of 80.31% and a negative net margin of 720.38%. View Signal Genetics' Earnings History.
Where is Signal Genetics' stock going? Where will Signal Genetics' stock price be in 2017?
3 brokers have issued 1-year target prices for Signal Genetics' stock. Their forecasts range from $17.00 to $29.00. On average, they expect Signal Genetics' share price to reach $23.00 in the next twelve months. View Analyst Ratings for Signal Genetics.
What are Wall Street analysts saying about Signal Genetics stock?
Here are some recent quotes from research analysts about Signal Genetics stock:
- 1. According to Zacks Investment Research, "Miragen Therapeutics, Inc. is a biopharmaceutical company. It develops microRNA biology, oligonucleotide chemistry, drugs and therapies for cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Miragen Therapeutics, Inc., formerly known as Signal Genetics, is headquartered in Boulder, Colorado. " (11/17/2017)
- 2. Chardan Capital analysts commented, "We see 6 positives in the MRG-106 oral presentation at EORTC The MRG-106 oral presentation at EORTC shows promising signals on the mycosis fungoides form of CTCL. On Saturday, October 13th, at the European Organisation for Research and Treatment of Cancer (EORTC) Global Task Force meeting, miRagen Therapeutics presented new interim phase I data of microRNA-155 inhibitor, MRG-106, in the mycosis fungoides (MF) form of cutaneous t-cell lymphoma (CTCL). The results showed 22/23 (96%) of MRG-106-treated patients had improvements in skin disease, when treated with either subcutaneous (subQ) or intravenous MRG-106, as measured by the maximal change in the modified Severity Weighted Assessment Tool (mSWAT) score, which measures the severity of skin disease over a patient’s body." (10/16/2017)
Who are some of Signal Genetics' key competitors?
Some companies that are related to Signal Genetics include ObsEva SA (OBSV), Syros Pharmaceuticals (SYRS), AVEO Pharmaceuticals (AVEO), NantHealth (NH), Pacific Biosciences of California (PACB), Tetraphase Pharmaceuticals (TTPH), ChemoCentryx (CCXI), Merus N.V. (MRUS), Rockwell Medical (RMTI), NewLink Genetics Corporation (NLNK), Nicox SA (NICXF), Ra Pharmctl (RARX), Arbutus Biopharma Corporation (ABUS), ChromaDex Corporation (CDXC), Geron Corporation (GERN), Aceto Corporation (ACET), BioSpecifics Technologies Corp (BSTC) and Edge Therapeutics (EDGE).
Who owns Signal Genetics stock?
Signal Genetics' stock is owned by many different of retail and institutional investors. Top institutional investors include SG Americas Securities LLC (0.13%), BSW Wealth Partners (0.10%), Russell Investments Group Ltd. (0.07%) and Seaward Management Limited Partnership (0.06%). Company insiders that own Signal Genetics stock include Adam Scott Levy and Kyle Lefkoff. View Institutional Ownership Trends for Signal Genetics.
Who bought Signal Genetics stock? Who is buying Signal Genetics stock?
Signal Genetics' stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, BSW Wealth Partners, Russell Investments Group Ltd. and Seaward Management Limited Partnership. View Insider Buying and Selling for Signal Genetics.
How do I buy Signal Genetics stock?
Shares of Signal Genetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Signal Genetics' stock price today?
One share of Signal Genetics stock can currently be purchased for approximately $8.04.
How big of a company is Signal Genetics?
Signal Genetics has a market capitalization of $179.37 million and generates $3.34 million in revenue each year. The medical research company earns $-12,670,000.00 in net income (profit) each year or ($8.93) on an earnings per share basis. Signal Genetics employs 45 workers across the globe.
How can I contact Signal Genetics?
Signal Genetics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 720-643-5200 or via email at [email protected]
MarketBeat Community Rating for Signal Genetics (MGEN)MarketBeat's community ratings are surveys of what our community members think about Signal Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Signal Genetics (NASDAQ:MGEN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$23.00 (186.07% upside)|
Consensus Price Target History for Signal Genetics (NASDAQ:MGEN)
Analysts' Ratings History for Signal Genetics (NASDAQ:MGEN)
(Data available from 11/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/16/2017||Chardan Capital||Reiterated Rating||Buy||$29.00||N/A|
|6/1/2017||Cowen Inc||Initiated Coverage||Outperform||Medium|
|8/21/2016||Rodman & Renshaw||Set Price Target||Buy||$4.00||N/A|
|1/8/2016||HC Wainwright||Initiated Coverage||Buy||$4.00||N/A|
Earnings History and Estimates Chart for Signal Genetics (NASDAQ:MGEN)
Earnings History by Quarter for Signal Genetics (NASDAQ MGEN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/8/2017||Q3 2017||($0.39)||($0.27)||$0.72 million||$1.63 million||View||N/A|
|8/11/2017||Q2 2017||($0.47)||($0.34)||$0.46 million||$0.72 million||View||N/A|
|5/10/2017||Q1 2017||($0.24)||($0.60)||$1.00 million||$0.46 million||View||N/A|
|5/16/2016||Q116||($0.28)||($0.26)||$645.00 million||$808.00 million||View||N/A|
|3/16/2016||Q415||($0.36)||($0.28)||$0.60 million||$0.66 million||View||N/A|
|5/14/2015||Q115||($0.36)||($0.45)||$1.90 million||$0.65 million||View||N/A|
|11/14/2014||Q3 2014||($0.05)||($0.43)||$1.30 million||View||N/A|
Earnings Estimates for Signal Genetics (NASDAQ:MGEN)
2017 EPS Consensus Estimate: ($1.16)
2018 EPS Consensus Estimate: ($1.44)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Signal Genetics (NASDAQ:MGEN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Signal Genetics (NASDAQ MGEN)
Insider Ownership Percentage: 44.40%
Institutional Ownership Percentage: 22.45%
Insider Trades by Quarter for Signal Genetics (NASDAQ MGEN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/22/2017||Adam Scott Levy||Insider||Buy||200||$7.55||$1,510.00|| |
|3/10/2017||Kyle Lefkoff||Director||Sell||5,800||$14.34||$83,172.00|| |
|3/8/2017||Kyle Lefkoff||Director||Sell||15,000||$15.40||$231,000.00|| |
|2/28/2017||Kyle Lefkoff||Director||Sell||10,258||$13.89||$142,483.62|| |
|2/23/2017||Kyle Lefkoff||Director||Sell||5,902||$14.14||$83,454.28|| |
|11/20/2015||Samuel D. Riccitelli||CEO||Buy||14,000||$0.79||$11,060.00|| |
Latest Headlines for Signal Genetics (NASDAQ MGEN)
|Cannabis Science (CBIS) & Signal Genetics (MGEN) Head-To-Head Review|
www.americanbankingnews.com - November 22 at 3:42 PM
|Contrasting Cannabis Science (CBIS) & Signal Genetics (MGEN)|
www.americanbankingnews.com - November 21 at 5:52 PM
|BG Medicine (BGMD) and Signal Genetics (MGEN) Critical Survey|
www.americanbankingnews.com - November 21 at 1:52 PM
|BG Medicine (BGMD) and Signal Genetics (MGEN) Head to Head Review|
www.americanbankingnews.com - November 20 at 1:30 AM
|Signal Genetics, Inc. (MGEN) Stock Rating Upgraded by Zacks Investment Research|
www.americanbankingnews.com - November 18 at 6:56 PM
|Cannabis Science (CBIS) versus Signal Genetics (MGEN) Critical Review|
www.americanbankingnews.com - November 17 at 3:08 AM
|Cannabis Science (CBIS) vs. Signal Genetics (MGEN) Head to Head Survey|
www.americanbankingnews.com - November 16 at 11:14 PM
|Signal Genetics (MGEN) vs. BG Medicine (BGMD) Head-To-Head Survey|
www.americanbankingnews.com - November 15 at 9:12 PM
|ETFs with exposure to Miragen Therapeutics, Inc. : November 14, 2017|
finance.yahoo.com - November 15 at 6:19 AM
|Miragen Therapeutics, Inc. :MGEN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017|
finance.yahoo.com - November 13 at 4:39 PM
|Signal Genetics, Inc. (MGEN) Releases Earnings Results|
www.americanbankingnews.com - November 9 at 6:04 PM
|Miragen Therapeutics, Inc. to Host Earnings Call|
finance.yahoo.com - November 8 at 6:01 PM
|miRagen Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update|
finance.yahoo.com - November 8 at 6:01 PM
|miRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the 2017 American Society of Hematology Annual Meeting|
finance.yahoo.com - November 2 at 6:19 AM
|miRagen Therapeutics to Announce Third Quarter 2017 Financial Results and Host Webcast Conference Call on November 8, 2017|
finance.yahoo.com - November 2 at 6:19 AM
|miRagen Therapeutics Announces Five Presentations at the DIA Oligonucleotide-Based Therapeutics Conference|
finance.yahoo.com - October 18 at 7:02 AM
|Featured Company News - Miragen Therapeutics Announces New Interim Results from Phase-1 Clinical Trial Assessing Safety and Pharmacokinetics of MRG-106|
finance.yahoo.com - October 16 at 8:14 PM
|Signal Genetics, Inc. (MGEN) Receives "Buy" Rating from Chardan Capital|
www.americanbankingnews.com - October 16 at 6:30 AM
|miRagen Therapeutics Presents New Clinical Data Suggesting Positive Impact From Systemically Administered MRG-106 on Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma at EORTC Global Task Force Meeting|
finance.yahoo.com - October 14 at 3:03 AM
|miRagen Therapeutics to Present at the Chardan Inaugural Gene Therapy Conference|
finance.yahoo.com - October 4 at 7:46 AM
|ETFs with exposure to Miragen Therapeutics, Inc. : October 3, 2017|
finance.yahoo.com - October 4 at 7:46 AM
|ETFs with exposure to Miragen Therapeutics, Inc. : September 19, 2017|
finance.yahoo.com - September 20 at 6:18 AM
|Miragen Therapeutics, Inc. :MGEN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017|
finance.yahoo.com - September 18 at 9:44 PM
|miRagen Therapeutics Presents New MRG-201 Preclinical Data for Inhaled MicroRNA-29 Mimic Targeting Pulmonary Fibrosis|
finance.yahoo.com - September 12 at 1:19 AM
|Miragen Therapeutics to Present New MRG-201 Preclinical Inhalation Data for Pulmonary Fibrosis at the European Respiratory Society International Congress|
finance.yahoo.com - September 2 at 6:12 AM
|BioTelemetry (BEAT) & Signal Genetics (MGEN) Head to Head Review|
www.americanbankingnews.com - August 29 at 8:06 PM
|Reviewing Signal Genetics (MGEN) and BioTelemetry (BEAT)|
www.americanbankingnews.com - August 27 at 2:28 AM
|Reviewing Signal Genetics (MGEN) & BioTelemetry (BEAT)|
www.americanbankingnews.com - August 24 at 8:38 AM
|Signal Genetics, Inc. (MGEN) Given Consensus Rating of "Buy" by Analysts|
www.americanbankingnews.com - August 19 at 12:52 PM
|Contrasting Signal Genetics (MGEN) & BioTelemetry (BEAT)|
www.americanbankingnews.com - August 19 at 10:48 AM
|Signal Genetics' (MGEN) Buy Rating Reaffirmed at Wedbush|
www.americanbankingnews.com - August 18 at 4:32 PM
|Signal Genetics, Inc. (MGEN) Posts Quarterly Earnings Results|
www.americanbankingnews.com - August 12 at 10:40 AM
|Signal Genetics, Inc. (NASDAQ:MGEN) Rating Reiterated by Chardan Capital|
www.americanbankingnews.com - August 12 at 6:34 AM
|miRagen Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update|
finance.yahoo.com - August 12 at 5:15 AM
|Reviewing BioTelemetry (BEAT) and Signal Genetics (NASDAQ:MGEN)|
www.americanbankingnews.com - August 11 at 10:52 PM
|miRagen Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference|
finance.yahoo.com - August 8 at 11:58 PM
|Signal Genetics (MGEN) versus BioTelemetry (BEAT) Financial Survey|
www.americanbankingnews.com - August 1 at 2:08 PM
|Signal Genetics (NASDAQ:MGEN) & BG Medicine (BGMD) Head-To-Head Survey|
www.americanbankingnews.com - July 27 at 2:42 PM
|Comparing BG Medicine (BGMD) & Signal Genetics (MGEN)|
www.americanbankingnews.com - July 26 at 12:26 AM
|Signal Genetics, Inc. (NASDAQ:MGEN) Given Average Recommendation of "Buy" by Analysts|
www.americanbankingnews.com - July 25 at 3:10 PM
|miRagen Therapeutics, Inc. (Nasdaq: MGEN) to Ring The Nasdaq Stock Market Closing Bell|
finance.yahoo.com - July 22 at 6:26 AM
|Comparing BG Medicine (BGMD) and Signal Genetics (MGEN)|
www.americanbankingnews.com - July 21 at 2:26 PM
|BG Medicine (BGMD) versus Signal Genetics (MGEN) Head-To-Head Review|
www.americanbankingnews.com - July 21 at 2:24 PM
|Miragen Therapeutics (MGEN) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow|
seekingalpha.com - June 8 at 10:23 AM
|Miragen Therapeutics (MGEN) Presents At UBS Global Healthcare Conference 2017 - Slideshow|
seekingalpha.com - May 24 at 10:44 AM
|miRagen Therapeutics (MGEN) Presents Interim Results from MRG-201 Phase 1 Clinical Trial|
www.streetinsider.com - April 27 at 7:05 PM
|4:15 pm Miragen Therapeutics reported recent clinical and financial highlights along with anticipated milestones for 2017|
us.rd.yahoo.com - April 4 at 3:51 AM
|MIRAGEN THERAPEUTICS, INC. Files SEC form 8-K/A, Financial Statements and Exhibits|
biz.yahoo.com - March 31 at 6:38 PM
|MIRAGEN THERAPEUTICS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Change in Directors or|
biz.yahoo.com - March 30 at 6:49 PM
|MIRAGEN THERAPEUTICS, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 24 at 6:33 PM
Signal Genetics (NASDAQ MGEN) Chart for Friday, November, 24, 2017